Print

iCo Therapeutics Inc. Extends Investor Relations Engagement with The Trout Group  
12/27/2010 9:55:55 AM

VANCOUVER, BRITISH COLUMBIA--(Marketwire - December 24, 2010) - iCo Therapeutics Inc. (TSX VENTURE: ICO) (the "Company") today announced that it has extended its previously announced agreement with The Trout Group LLC ("The Trout Group") until November 30, 2011. The Trout Group is a leading New York based investor relations and strategic advisory firm to the life sciences industry. Effective December 1, 2010, the Company will pay The Trout Group a quarterly retainer of US$24,000. Either the Company or Trout may terminate the Agreement by providing thirty days prior written notice to the other.

The Trout Group is not related to iCo, nor do they have any interest, directly or indirectly, in the Company's securities.

About iCo Therapeutics

iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications. iCo has exclusive worldwide rights to three products: iCo-007, moving into Phase II for the treatment of DME, iCo-008; a product with Phase II clinical history to be developed for severe ocular allergies and age-related macular degeneration; and iCo-009, an oral formulation of Amphotericin B for sight and life-threatening diseases. iCo granted a license option for iCo-008 systemic uses to Immune Pharmaceuticals in December 2010. iCo-009 also represents a new drug delivery technology with the potential to reprofile other parenteral administered drugs to the oral route of administration. iCo was recently awarded a Gold Leaf Award as the Early Stage Company of the Year from BIOTECanada and is a Canada's Top 10™ Competition winner. iCo trades on the TSX Venture Exchange under the symbol "ICO". For more information, visit the Company website at: www.icotherapeutics.com.

Forward Looking Statements

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo Therapeutics' current beliefs as well as assumptions made by and information currently available to iCo Therapeutics and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by iCo Therapeutics in its public securities filings; actual events may differ materially from current expectations. iCo Therapeutics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

No regulatory authority has approved or disapproved the content of this release. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.


Contacts:
iCo Therapeutics Inc. - Finance
Mr. John Meekison
CFO
604-602-9414 x 224

iCo Therapeutics Inc. - Investor/Media Contact
Frederica Jensen
604-602-9414 x 226
www.icotherapeutics.com


//-->